News from zafgen, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 28, 2014, 07:00 ET

Zafgen Announces Support of NORD in Observing Rare Disease Day

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it will join...

Jan 15, 2014, 07:00 ET

Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced initial...

Jan 09, 2014, 08:00 ET

Zafgen to Present at 32nd Annual J.P. Morgan Healthcare Conference

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that...

Jan 09, 2014, 07:00 ET

Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced the...

Dec 04, 2013, 08:00 ET

Zafgen Secures $45 Million in Series E Financing

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has...

Nov 15, 2013, 07:00 ET

Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final...

Jun 22, 2013, 11:00 ET

Zafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association's 73rd Scientific Sessions®

 Zafgen, Inc. today announced new data from an interim analysis conducted from an ongoing Phase 2 study of beloranib, a selective methionine...

Jan 04, 2013, 08:30 ET

Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced the...

Dec 04, 2012, 08:00 ET

Zafgen Secures $21 Million in Series D Financing

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has...

Nov 06, 2012, 08:00 ET

Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that it has...

Sep 22, 2012, 13:00 ET

Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced new data...

Jun 10, 2012, 10:56 ET

Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association's 72nd Scientific Sessions®

Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new...